Business Context and Reporting Period
Company: ASPAC III Acquisition Corp. (BVI)
Filing Date: May 23, 2025
Event: Entry into a Material Definitive Agreement (Merger Agreement) to combine with Bioserica International Limited.
Structure: The transaction involves a Reincorporation Merger (Parent into Purchaser) followed by an Acquisition Merger (Merger Sub into Bioserica). Bioserica will be the surviving corporation.
Key Financial Metrics and Transaction Terms
Acquisition Consideration: $200,000,000 aggregate value paid entirely in stock.
- Primary Component: Newly issued Class B Ordinary Shares of the Purchaser at $10.00 per share.
- Secondary Component: Up to 1,786,000 Purchaser Class A Ordinary Shares (determined per agreement terms).
Financial Data: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either ASPAC III or Bioserica. It references the delivery of audited financial statements as a condition to closing.
Material Changes and Agreements
Termination of Prior Agreement: On May 21, 2025, the Company terminated a mutual indication of interest agreement with HDEducation Group Limited.
Shareholder Support: A Voting and Support Agreement was executed with a Bioserica shareholder to vote in favor of the merger and refrain from transferring shares until closing or termination.
Lock-Up Provisions: Shareholders will enter a 365-day lock-up agreement. 20% of shares may be released early if the stock price exceeds $15.00 for 20 trading days within a 30-day period after 180 days post-closing.
Guidance, Risks, and Conditions to Closing
Conditions to Closing:
- SEC declaration of registration statement effectiveness.
- Shareholder approval from both ASPAC III and Bioserica.
- Completion of CSRC (China Securities Regulatory Commission) filing and receipt of certificates.
- Completion of cybersecurity review filing with the CAC (Cyberspace Administration of China).
- No material adverse effect on either party.
Termination Rights:
- Purchaser may terminate if audited financial statements are not delivered by May 31, 2025.
- Either party may terminate if the transaction is not closed by October 30, 2025.
- Either party may terminate if the CAC cybersecurity review is revoked or the CSRC rejects the transaction.
Risks: Risks include failure to obtain shareholder approval, high redemption rates impacting trust account liquidity, regulatory delays (SEC, CSRC, CAC), and general market conditions.
Investor Verification Checklist
- Verify the status of the CSRC filing and CAC cybersecurity review, as these are explicit termination triggers.
- Confirm the delivery of Bioserica's audited financial statements by the May 31, 2025 deadline.
- Review the upcoming proxy statement/prospectus for detailed financial data on Bioserica and redemption rights.
- Monitor the October 30, 2025 deadline for transaction consummation.
- Assess the potential impact of shareholder redemptions on the combined company's cash position.